

September 5, 2025

## **Approval for Marketing Authorization for Efinaconazole in Germany for the Treatment of Onychomycosis**

Kaken Pharmaceutical Co., Ltd. (“Kaken”, head office Bunkyo-ku, Tokyo; President and Representative Director, Hiroyuki Horiuchi) announced that Almirall S.A. (“Almirall”, head office Barcelona, Spain) has obtained approval from BfArM: Bundesinstitut für Arzneimittel und Medizinprodukte (Federal Institute for Drugs and Medical Devices) for the marketing authorization in Germany of Jublia<sup>®</sup>, a topical formulation drug for onychomycosis (generic name: efinaconazole; product name in Japan: Clenafin<sup>®</sup>) after the completion of the decentralized regulatory procedure.

In July 2021, Kaken and Almirall entered into an agreement under which Kaken granted Almirall the exclusive right for the development and commercialization of Jublia in Europe. Subsequently, Almirall submitted applications for marketing authorization in Italy and Germany. After receiving marketing authorization in Italy in March 2025, the approval in Germany is the second marketing authorization in Europe obtained by Almirall.

### **About Almirall S.A.**

Almirall is a global pharmaceutical company dedicated to medical dermatology that closely collaborate with leading scientists, healthcare professionals, and patients to deliver its purpose: to transform the patients' world by helping them realize their hopes and dreams for a healthy life. Almirall is at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients' needs.

Almirall, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM, total revenue in 2024: €990 MM, over 2000 employees globally). Almirall products help to improve the lives of patients every day and are available in over 100 countries.

**For more information, please visit <https://www.almirall.com/>**

### **Cautionary notes regarding forward-looking statement**

*This release contains forward-looking statements on the Kaken group's business. They are projections based on information available at the time this release was prepared, and may differ from actual results due to a variety of factors. In addition, although this release includes information related to pharmaceutical products (including those under development), these statements are not intended to be advertisement or medical advice.*